Finanzen von Utah Medical Products Inc (UTMD)UTMDUtah Medical Products Inc

Utah Medical Products Inc (UTMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Gynecology/Electrosurgery/Urology, accounting for 59.9% of total sales, equivalent to $5.23M. Other significant revenue streams include Neonatal and Blood Pressure Monitoring and Accessories. Understanding this composition is critical for investors evaluating how UTMD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Utah Medical Products Inc maintains a gross margin of 60.56%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 29.41%, while the net margin is 29.86%. These profitability ratios, combined with a Return on Equity (ROE) of 9.14%, provide a clear picture of how effectively UTMD converts its operational activities into shareholder value.

In the context of the broader market, UTMD competes directly with industry leaders such as STIM and ORGO. With a market capitalization of $228.09M, it holds a significant position in the sector. When comparing efficiency, UTMD's gross margin of 60.56% stands against STIM's 51.06% and ORGO's 45.90%. Such benchmarking helps identify whether Utah Medical Products Inc is trading at a premium or discount relative to its financial performance.

The company has demonstrated consistent profitability, with a net income of $2.6 million in Q1 2026 and a gross margin of 60.56%, indicating effective cost management and operational efficiency.